Key result
Aggressive therapy fails to prevent heart transplantation within 8 months in rapidly progressive cardiac sarcoidosis.
Why the study?
Cardiac sarcoidosis is an inflammatory cardiomyopathy with heterogeneous presentation and life-threatening complications, where early diagnosis is challenging and optimal treatment requires a multidisciplinary approach.
Case Report (n=1)
Cardiac sarcoidosis can rapidly progress to irreversible myocardial fibrosis and end-stage heart failure requiring transplantation despite aggressive immunosuppressive therapy and metabolic remission.
Answers are grounded in this paper and cite their sources.
Rapid decompensation possible in systemic sarcoidosis; leaves open optimal screening and arrhythmia strategies.
Cardiac sarcoidosis (CS) is an inflammatory cardiomyopathy with heterogeneous presentation and potentially life-threatening complications, including ventricular arrhythmia, atrioventricular block, and heart failure. Early diagnosis is challenging and a multidisciplinary approach is pivotal for optimal treatment and better outcome. We report the case of a 47-year-old man with newly diagnosed systemic sarcoidosis who rapidly developed heart failure and therapy-refractory ventricular arrhythmias despite combined immunosuppressive and antiarrhythmic therapy. Within eight months from the first diagnosis of CS, the patient required four hospitalizations, ICD implantation, ventricular tachycardia ablation, and ultimately orthotopic heart transplantation. Histological examination of the explanted heart revealed extensive myocardial fibrosis without residual granulomas or inflammation, consistent with end-stage, burned-out CS—highlighting the irreversibility of myocardial damage once the fibrotic phase has developed. This case illustrates the potentially devastating course of CS despite aggressive immunosuppressive therapy, emphasizing that the overall prognosis of sarcoidosis disease is largely influenced by cardiac manifestation. Indeed, complete metabolic remission based on a serial FDG-PET/CT scan did not prevent progressive functional deterioration—underscoring that irreversible myocardial fibrosis may progress beyond maximal medical therapy, including anti-inflammatory, immunosuppressive and neuro-humoral treatment. Therefore, prompt screening for CS is essential, and once cardiac involvement is suspected and respectively confirmed, the therapy window may become particularly narrow in the case of rapidly progressive CS.
No takes yet. Share an insight, caveat, or question.
Rantas et al. (2026) conducted a case report in Cardiac sarcoidosis (n=1). Immunosuppressive and antiarrhythmic therapy, ICD implantation, VT ablation, and orthotopic heart transplantation was evaluated on Clinical course and heart transplantation. A 47-year-old man with cardiac sarcoidosis required heart transplantation within 8 months of diagnosis due to rapidly progressive heart failure and refractory ventricular arrhythmias despite aggressive therapy.
Synapse has enriched 10 related papers. Consider them for comparative context: